Amylyx Pharmaceuticals, Inc.

AMLX

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
April 09, 2024

Days Left:
-247

calendar

Amylyx Pharmaceuticals, Inc. Form












Class Action Lawsuit List does not share your information with others. There is no cost or obligation for you to submit.

Allegations

The filed complaint alleges that defendants made false statements and/or concealed that: (i) defendants had overstated commercial prospects RELYVRIO, a dual UPRBax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the U.S.; (ii) patients were discontinuing treatment with RELYVRIO after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) accordingly, defendants had also overstated RELYVRIO’s prescription rate; (v) defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing RELYVRIO’s prescription data; and (vi) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Amylyx purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Amylyx during the relevant time frame, you have until April 09, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Active Cases

Ticker Symbol Company Name Join Deadline Join
EW Edwards Lifesciences Corporation December 13, 2024 Join
TD The Toronto-Dominion Bank December 23, 2024 Join
WOLF Wolfspeed, Inc. January 17, 2025 Join